LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer

X. Xue, Y. A. Yang, A. Zhang, K. W. Fong, J. Kim, B. Song, S. Li, J. C. Zhao, J. Yu*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

354 Scopus citations


Tamoxifen, an estrogen receptor (ER) antagonist, is the mainstay treatment of breast cancer and the development of resistance represents a major obstacle for a cure. Although long non-coding RNAs such as HOTAIR have been implicated in breast tumorigenesis, their roles in chemotherapy resistance remain largely unknown. In this study, we report that HOTAIR (HOX antisense intergenic RNA) is upregulated in tamoxifen-resistant breast cancer tissues compared to their primary counterparts. Mechanistically, HOTAIR is a direct target of ER-mediated transcriptional repression and is thus restored upon the blockade of ER signaling, either by hormone deprivation or by tamoxifen treatment. Interestingly, this elevated HOTAIR increases ER protein level and thus enhances ER occupancy on the chromatin and potentiates its downstream gene regulation. HOTAIR overexpression is sufficient to activate the ER transcriptional program even under hormone-deprived conditions. Functionally, we found that HOTAIR overexpression increases breast cancer cell proliferation, whereas its depletion significantly impairs cell survival and abolishes tamoxifen-resistant cell growth. In conclusion, the long non-coding RNA HOTAIR is directly repressed by ER and its upregulation promotes ligand-independent ER activities and contributes to tamoxifen resistance.

Original languageEnglish (US)
Pages (from-to)2746-2755
Number of pages10
Issue number21
StatePublished - May 1 2016

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research


Dive into the research topics of 'LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer'. Together they form a unique fingerprint.

Cite this